BioSurgical Innovations, Inc. is marketing new technologies in surgical biomaterials throughout Latin America that offer physicians and their patients’ alternative surgical and treatment options. These innovative products are designed to interact with living tissue and have the capacity to improve procedural efficiencies for surgeons and enhance the clinical outcomes and quality of life for their patients.

BioSurgical Innovations, Inc., a startup sales and distribution company based in South Florida, is bringing to market new technologies in surgical biomaterials that offer physicians and patients alternative surgical and treatment options. The company, which recently opened its headquarters in the Sawgrass International Corporate Park in Broward County, is focused on marketing these innovative new products throughout Latin America and the Caribbean in an effort to help improve the quality of life of patients in those regions.

The surgical biomaterials market is one of the fastest growing medical markets in the U.S. and encompasses a number of different specialties. Biomaterial implants and devices have the ability to lower procedure times, reduce recovery periods and lessen complication rates, while at the same time providing clinicians with innovative approaches to improving the level of patient care.

Some of the benefits of biomaterials can be seen in their use in surgeries that typically use “autografts”. This is when surgeons take tissue (or bone) from one part of the patient’s body and then place it in another part of their body in order to repair a defect or replace diseased tissue. One of the most common procedures in which autografts are used is spinal fusion, a surgery in which one or more vertebrae of the spine are welded together with the aim of eliminating painful motion.

During a spinal fusion, the surgeon makes an incision in the patient’s hip and removes a piece of bone from the pelvis, which is then implanted in the space between the vertebrae and held in place by metal fasteners. The pain and problems associated with motion are reduced over time, as the implanted bone and vertebrae grow into a single, solid bone. Some of the major disadvantages of autografts in these procedures are the additional operating time it takes the surgeon to harvest the graft, the extra postoperative recovery time needed and the added pain the patient must endure at the harvest site. Synthetic or animal based biomaterial bone substitutes provide surgeons and their patients with an option that lessen time under anesthesia and cut down on recovery time.

“These are exciting technologies that have the potential to greatly improve the quality of life for patients that live in countries where technology sometimes lags significantly behind advances in the U.S. and Europe,” said Vincent S. Fall, Executive Director of BioSurgical Innovations. “We hope to change that in the surgical biomaterial arena by leveraging our relationships with surgeon thought leaders, teaching institutions and distribution partners in the geography that we are targeting.”

BioSurgical Innovations is identifying and bringing biomaterial technologies to the Latin American market for a number of specialties including spine, neurosurgery, orthopedics, general surgery, oral surgery, facial aesthetic plastic and reconstructive surgery and wound care. Whether synthetic or natural in origin, these products are designed to interact with living tissue and have the capacity to improve procedural efficiencies for surgeons and enhance the clinical outcomes and quality of life for their patients.

For additional information, contact:
Joseph R. Lopez
BioSurgical Innovations, Inc.
Tel: 954-331-8044
Fax: 954-331-4601
http://www.bsurgical.com